Safety profiles of calcineurin inhibitor-related infections in the pediatric population: a real-world pharmacovigilance analysis.

Authors

Yun Lu, Yan Zhou, Yu Wu, Chun Liu, Lu Zhou, Ya Zou, Hua Wei, Fangqing Xie, Hongju Wang, Shihao Yan, Xirui Guo, Qinchuan Li, Jia Chen

Published in

European journal of pediatrics. Volume 185. Issue 10. Sep 19, 2026. Epub Sep 19, 2026.

Abstract

This study aimed to assess infection-related adverse events (AEs) associated with calcineurin inhibitors (CNIs), including cyclosporine (CsA) and tacrolimus (TAC), in the pediatric population using combined postmarketing surveillance databases. Data from the FDA Adverse Event Reporting System (FAERS) and the Japanese Adverse Drug Event Report (JADER) were analyzed for pediatric patients. Disproportionality analysis was conducted to evaluate AEs. Additionally, subgroup analysis, fatal outcome assessment, and time-to-onset (TTO) analysis were also performed. A total of 426 CsA-related and 1284 TAC-related infection reports were identified in FAERS, with corresponding findings in JADER (CsA, n = 140; TAC, n = 323). Cross-database analysis identified positive overlapping signals for BK virus, cytomegalovirus, and Epstein-Barr virus infections for both drugs. Age- and sex-stratified analysis revealed differences in infection-related reporting patterns, with the percentage of fatal outcomes varying significantly across age groups and being highest in the youngest subgroups: 3-5 years for CsA (29.2%) and 0-2 years for TAC (18.4%) (P < 0.05).
 This study provides real-world evidence on infection-related safety signals associated with CNIs in pediatric patients, particularly for viral infections. The distinct signal profiles and age- and sex-specific patterns highlight the importance of individualized infection risk monitoring and immunosuppressive management strategies.
• Calcineurin inhibitors (CNIs), including cyclosporine (CsA) and tacrolimus (TAC), are widely used in pediatric transplantation and immune-mediated diseases, but infection remains an important safety concern during CNI-based immunosuppression. • Evidence on the comparative infection-related safety profiles of these two agents in children remains limited.
• This is the first dual-database pharmacovigilance analysis to characterize infection-related safety signals associated with CsA and TAC in pediatric patients. • Age- and sex-specific patterns were identified, with fatal outcomes significantly associated with younger age groups for both drugs.

PMID:
42760444
Bibliographic data and abstract were imported from PubMed on 19 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.